Move over Vascepa, here comes Epanova

|By:, SA News Editor

The FDA approves AstraZeneca's (AZN) Epanova (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (>=500 mg/dl). It is the first approved omega-3 in free fatty acid form. Patients can take as few as two capsules/day.

In some patients Epanova increases LDL-Cholesterol so this parameter should be monitored periodically during therapy. This will undoubtedly be a selling point for Amarin's (AMRN) Vascepa (icosapent ethyl) since it lowers LDL-C.